Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan in Metastatic Colorectal Cancer
NCT00002933Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Sep 1996
- Primary completion
- Jul 2000
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC), sponsored by Case Comprehensive Cancer Center. Started Sep 1996; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00002933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002933.